Skip to main content

Table 4 Effect on daily activities following administration of pilocarpine solution to patients with Sjӧgren’s syndrome

From: New low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren’s syndrome: clinical efficacy, symptom relief, and improvement in quality of life

Item VAS (5 cm) a
Pre-administration Continuous administration
General activities (n = 21) 2.4 (1.2, 3.3) 1.0 (0.3, 2.0)**
Normal work (n = 21) 2.4 (1.0, 3.4) 1.0 (0.4, 2.1)
Interpersonal relationships (n = 20) 2.4 (1.5, 3.2) 1.4 (0.7, 2.4)**
Food intake (n = 18) 2.6 (1.0, 4.0) 1.4 (0.7, 3.0)*
Sleep (n = 20) 2.4 (0.8, 2.7) 1.5 (0.7, 2.5)
Appetite (n = 20) 0.9 (0.6, 2.4) 1.1 (0.5, 1.7)
  1. *: Significantly different from pre-administration at P < 0.05; **: P < 0.01 (Wilcoxon signed-rank test)
  2. aVAS, visual analog scale; Median (1st quartile, 3rd quartile)
\